



THERAMED ANNOUNCES NEW PRODUCT LAUNCH AND SALES ORDERS FOR NEVADA FACILITY, AND FINANCING UPDATE

VANCOUVER, BC, Wednesday May 22, 2019 – THERAMED HEALTH CORP. (CSE: TMED, OTCQB: EVAHF) (the “**Company**”) is pleased to announce a first round of sales for its new product line from its flagship Hemp processing facility in Las Vegas, Nevada.

THERAMED’S US facility headquartered in Las Vegas, Nevada, has just launched its new product line of tinctures, skin products, and confections. Following its successful launch, the company has landed orders for several of its product lines.

Through a series of LOIs from multiple vendors the company expects purchase orders in excess of 120,000 units every two-month period. The exact quantity fulfilled every month may exceed the original estimate as determined by the buyers’ demand and the product success. "I am extremely pleased to introduce our new product line and not surprised to see the immediate interest in our products. I feel at Theramed, we offer a line of products that have more thought put towards consumer needs, and with our team's superior processing abilities, we will continue to separate ourselves from other CBD lines and companies" states CEO CK Cheung.

Update on non-brokered private placement financing; the company is pleased to report that it received a total of \$705,000 of funds towards the first tranche closing.

Further the Company continues to develop products, technologies, and diagnostic tools focused on hemp derived CBD. The products will serve with the overall goal of improving health and elevating the human condition.

THERAMED HEALTH CORPORATION

Email theramedhealthcorp@gmail.com

Website <http://www.theramedhealthcorp.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/Theramed-Health-Corporation>

US OTC Markets (OTCQB): <http://www.otcm Markets.com/stock/EVAHF/news>

About THERAMED HEALTH

(CSE: TMED, OTCQB: EVAHF)

Theramed Health Corporation – is a technology company focused in the healthcare and life sciences sector to develop a personalized healthcare system. The company has recently been focused on utilizing CBD derived from Hemp as a core component. The company through its subsidiaries has assets and technologies involved in extracting and purifying CBD extracts, creating formulations through its key scientists, and with its medical device technology monitoring capabilities. Theramed’s unique combination of technologies may allow it to be the first to be able to offer a complete quality assured vertically integrated “CBD Health System” for monitoring, dosing, and recording the effects of CBD on your cardiovascular system.

Disclaimers

This news release contains forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators and on the OTC Markets website which is posted on www.sedar.com, <http://thecse.com/en/listings/technology/Theramed-Health-Corporation>, and <http://www.otcmarkets.com/stock/EVAHF/filings>. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), or any other regulatory authority accepts responsibility for the adequacy or accuracy of this release. The Company does not undertake to update this news release unless required by applicable law.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.